This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
For some wine styles, such as light, fruity wines or for low-acid wines from warm climates, malolactic fermentation is not desired. Winemakers can take several steps to prevent MLF from taking place, including:
The near-infrared region spans the wavelength range between the rock-salt region and the start of the visible region at about 750 nm. Overtones of fundamental vibrations can be observed in this region. It is used mainly in industrial applications such as process control and chemical imaging.
In Canada and the United States, half and half almost always refers to a light cream typically used in coffee. (See above.) The name refers to the liquid's content of half milk and half cream. It is widely available in the United States, both in individual-serving containers and in bulk. It is also used to make ice cream. Non-fat versions of the product are also available, containing corn syrup and other ingredients. This half and half can be also used to make a dirty soda. In addition to the light coffee cream, half and half can refer to other drinks in some regions of the U.S. A half and half of iced tea and lemonade is popular in the Northeastern United States. It consists of one part iced tea, sweetened, unsweetened or both, and one part lemonade served over ice. This drink is also called an Arnold Palmer, named for an American golfer, but that drink more correctly is mostly tea with one-quarter to one-third lemonade. In the Southern United States (specifically the cities of Atlanta and Houston), "half and half" may also refer to a mixture of half sweet and half unsweetened iced tea. Some coffee shops in colder climates serve a half and half drink consisting of half coffee and half hot chocolate, similar to caffè mocha. Half and half might also refer to a flavor of soda that combines the flavors of grapefruit and lemon.
=== In other tumors === CD10 expression might be one of the characteristics of müllerian system-derived neoplastic mesenchymal cells. Normal endometrial stroma Endometrial stromal sarcoma (ESS) are CD10+ (Smooth muscle tumors are usually CD10−, but can be CD10+ Malignant müllerian mixed tumor (MMMT) Müllerian adenosarcoma Uterine high-grade leiomyosarcoma Uterine rhabdomyosarcoma Vascular tumors Epithelioid hemangioendothelioma are mostly CD10+. Hemangioblastoma is usually CD10− (metastatic renal cell carcinoma is CD10+)
Sources: en.wikipedia.org
== Physiological function == Until the late 1970s, hyaluronic acid was described as a "goo" molecule, a ubiquitous carbohydrate polymer that is part of the extracellular matrix. For example, hyaluronic acid is a major component of the synovial fluid and was found to increase the viscosity of the fluid. Along with lubricin, it is one of the fluid's main lubricating components. Hyaluronic acid is an important component of articular cartilage, where it is present as a coat around each cell (chondrocyte). When aggrecan monomers bind to hyaluronan in the presence of HAPLN1 (hyaluronic acid and proteoglycan link protein 1), large, highly negatively charged aggregates form. These aggregates imbibe water and are responsible for the resilience of cartilage (its resistance to compression). The molecular weight (size) of hyaluronan in cartilage decreases with age, but the amount increases. A lubricating role of hyaluronan in muscular connective tissues to enhance the sliding between adjacent tissue layers has been suggested. A particular type of fibroblasts, embedded in dense fascial tissues, has been proposed as being cells specialized for the biosynthesis of the hyaluronan-rich matrix. Their related activity could be involved in regulating the sliding ability between adjacent muscular connective tissues. Hyaluronic acid is also a major component of skin, where it is involved in repairing tissue. When skin is exposed to excessive UVB rays, it becomes inflamed (sunburn), and the cells in the dermis stop producing as much hyaluronan and increase the rate of its degradation.
=== Absorption and distribution === Oral bioavailability has been found to be 8% ±6% on its own and, when co-administered with cyclosporine, bioavailability increased to 90% ± 44%. In practice, docetaxel is administered intravenously only to increase dose precision. Evaluation of docetaxel pharmacokinetics in phase II and III clinical studies were with 100 mg/m2 dosages given over one-hour infusions every three weeks. Docetaxel was shown to be greater than 98% plasma protein bound independent of concentration at 37 °C and pH 7.4 Docetaxel's plasma protein binding includes lipoproteins, alpha1 acid glycoprotein and albumin. Alpha1 acid glycoprotein is the most variable of these proteins inter-individually, especially in cancer patients and is therefore the main determinant of docetaxel's plasma binding variability. Docetaxel interacted little with erythrocytes and was unaffected by the polysorbate 80 in its storage medium. Polysorbate 80 may be the cause of hypersensitivity reasons in taxanes as recent studies indicated. The concentration-time profile of docetaxel was consistent with a three-compartment pharmacokinetic model. An initial, relatively rapid decline, with an α half-life of mean 4.5 minutes is representative of distribution to peripheral compartments from the systemic circulation. A β half-life of mean 38.3 minutes and a relatively slow γ half-life of mean 12.2 hours represent the slow efflux of docetaxel from the peripheral compartment.
Buttenwieser (1958), educator, Democratic Party fundraiser, member of the Lehman family Allen Rosenshine (1959), founder of the Omnicom Group, chairman and CEO of BBDO Doug Morris (1960), CEO of Sony Music Entertainment and former CEO of Universal Music Group Bernard Selz (1960), fund manager, philanthropist and anti-vaccination supporter Frank Lorenzo (1961), former chairman of Eastern Airlines, Texas Air Corporation and Texas International Airlines Douglas H. McCorkindale (1961), former chairman and CEO of Gannett William Campbell (1962), chairman of the board of Intuit, former board director of Apple Inc.; founder of Claris Sanford Greenberg (1962), investor, author and philanthropist Kenneth Lipper (1962), financier and deputy mayor of New York City; Academy Award-winning producer of The Holocaust documentary The Last Days Jerry Speyer (1962), billionaire, founding partner, chairman and CEO of Tishman Speyer and chairman of the Museum of Modern Art Robert Kraft (1963), chairman and CEO of The Kraft Group; owner of the New England Patriots Mark H.
== Classification == Wounds can be broadly classified as either acute or chronic based on time from initial injury and progression through normal stages of wound healing. Both wound types can further be categorized by cause of injury, wound severity/depth, and sterility of the wound bed. Several classification systems have been developed to describe wounds and guide their management. Some notable classification systems include the CDC's Surgical Wound Classification, the International Red Cross Wound Classification, the Tscherne classification, the Gustilo-Anderson classification of open fractures, and the AO soft tissue grading system.
Diabetes, Obesity and Metabolism is a monthly peer-reviewed medical journal established in 1999 covering research on diabetes, obesity, and metabolism. The journal has a 2024 Clarivate impact factor of 5.7. The journal publishes on topics such as pharmacokinetics and pharmacodynamics, cost-effectiveness, real world evidence of drug utilisation, safety and effectiveness, as well as conventional randomized controlled trials (phase I-IV studies).
Sources: en.wikipedia.org
=== August === 6 August – Tom O'Connor, journalist, author, senior citizens' advocate and local politician, president of Grey Power (2016–2018), Waimate District Councillor (since 2013) (born 1944). 8 August Judy Bailey, pianist, composer, jazz musician and educator (Sydney Conservatorium of Music), and television presenter (Play School) (born 1935). Peter Lester, sailor, sailing coach and commentator, OK dinghy world champion (1977), Admiral's Cup winner (1987, 1993) (born 1954). 10 August – Patrick Waddington, Russian linguist, literary critic and historian (Victoria University of Wellington) (born 1934). 13 August – Grant Tavinor, philosopher (Lincoln University) (born c. 1973). 15 August – John Rowan, lawyer, King's Counsel (since 1997) (born 1944). 16 August – Janet Grieve, biological oceanographer (New Zealand Oceanographic Institute, NIWA), New Zealand Association of Scientists president (1998–2000), World Association of Copepodologists president (2008–2011) (born 1940). 17 August – John Bartley, cinematographer (Lost, The X Files, The Chronicles of Riddick), Emmy Award (1996) (born 1947). 18 August Lloyd Ashby, rugby union player (Southland, national team) (born 1931). Lindsay Sparks, cricketer (Central Districts, Auckland) and rugby union player (Marlborough) (born 1944). 19 August – Tony Smith, legal scholar (University of Reading, University of Cambridge, Victoria University of Wellington) (born 1947). 21 August Evelyn Attwood, tennis player (born 1924). Keith Nelson, rugby union player (Otago, Auckland, national team) and dentist (born 1938).
== O == Obex The point in the brainstem where the fourth ventricle narrows to become the central canal of the spinal cord. Used as an anatomical landmark in neuroanatomy. Occipital lobe The rearmost lobe of the cerebral cortex, primarily responsible for visual processing, including interpretation of color, motion, and spatial orientation. Ocular dominance A preference of neurons in the visual cortex for input from one eye over the other. Studied extensively in visual development and plasticity. Oculomotor nerve (Cranial Nerve III) A cranial nerve that controls most of the eye's movements, including those of the eyelid and pupil constriction. Damage may result in diplopia or ptosis. Olfaction The sense of smell, mediated by receptors in the olfactory epithelium and processed in the olfactory bulb and related brain regions. Olfactory bulb The first brain structure to process olfactory (smell) information. Receives input from sensory neurons in the nasal cavity and sends projections to the olfactory cortex and limbic system. Olfactory cortex A region of the brain involved in odor identification and perception. Includes the piriform cortex and parts of the amygdala and entorhinal cortex. Olfactory nerve (Cranial Nerve I) The first cranial nerve, responsible for transmitting smell information from the nose to the brain. Oligodendrocyte A type of glial cell in the central nervous system that forms the myelin sheath around axons, enabling rapid signal conduction.
== Early life and legal career == Kerry-Lynne Findlay was born in 1955 in Ladysmith, British Columbia, and lived in Nanaimo and Victoria; her brother Greg Findlay was a linebacker for the BC Lions Canadian Football League (CFL) team. She comes from a family with many former CFL players; Findlay's father Stephen Findlay played for the Hamilton Tigers in the 23rd Grey Cup. After graduating from Crofton House School in Vancouver, she attended the University of British Columbia, receiving a Bachelor of Arts degree in history and political science in 1975, and a law degree in 1978. She articled at Kowarsky and Company in Vancouver, then worked there as an associate for two years before briefly serving as in-house counsel for the Insurance Corporation of British Columbia. She established her own practice in 1981, then joined Connell Lightbody in 1987 before switching to Watson Goepel Maledy in 1996. During her legal career, Findlay has been active in both the national and B.C. provincial branch of the Canadian Bar Association. She held various positions in that organization including national and provincial chair of the Constitutional Law Section and member of the National Task Force on Canadian Court Reform, and she was acclaimed president of the B.C. Branch for the 1997–1998 term. Findlay was appointed Queen's Counsel in March 1999 by the Attorney General of British Columbia, and served a five-year term as a Member of the Canadian Human Rights Tribunal by appointment of the Federal Minister of Justice (2006–2011).
CoA-glutathione + NADPH + H+ The 3 substrates of this enzyme are CoA, glutathione, and NADP+, whereas its 3 products are CoA-glutathione, NADPH, and H+. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is glutathione:NADP+ oxidoreductase (CoA-acylating). Other names in common use include coenzyme A glutathione disulfide reductase, NADPH-dependent coenzyme A-SS-glutathione reductase, coenzyme A disulfide-glutathione reductase, and NADPH:CoA-glutathione oxidoreductase. This enzyme participates in cysteine metabolism. It employs one cofactor, FAD.
== Risks == The use of sedative medications in older people generally should be avoided. These medications are associated with poorer health outcomes, including cognitive decline, fall, and bone fractures. Sedatives and hypnotics should also be avoided in people with dementia, according to the clinical guidelines known as the Medication Appropriateness Tool for Comorbid Health Conditions in Dementia (MATCH-D). The use of these medications can further impede cognitive function for people with dementia, who are also more sensitive to side effects of medications. Some hypnotics, such as low-dose doxepin, melatonin receptor agonists, and orexin receptor antagonists, may be safer and more appropriate in older adults however.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.